

Inpatient Gu	idelines for the T	reatment of Pneumonia – November 2023
		toms and at least one radiographic criteria as listed below:
\geq 2 Clinical Signs or Sympton		Radiographic Criteria (CXR or CT)
• Cough		Definitely Positive
• Sputum		 Air space density/opacity/disease
• Dyspnea or tachypnea		 Bronchopneumonia
• Hypoxia		Cavitation
• Exam finding (i.e. rales, crackles, etc.)		Ground glass
• Fever or hypothermia		• Infection
• WBC >10,000 or < 4,000/mcl or >15%		• Infiltrate
bands		Loculations
HMS-Preferred empiric treatment for CAP		Nodular airspace disease
includes:		Pleural effusion
- Ampicillin-Sulbactam PLUS Azithromycin,		Pneumonia
Clarithromycin, or Doxycycline		• Tree in bud
- Ceftriaxone or Cefotaxime PLUS Azithromycin,		
Clarithromycin, or Doxycycline		"cannot rule out pneumonia"
		"atelectasis vs. pneumonia"
X 0 (1		Alternative but HMS
Infection	Antimicrobial	Duration Non-Preferred Comments
· · · · · · · · · · · · · · · · · · ·	V Therapy [§]	treatment
Community-acquired	Ceftriaxone 1g IV	5 days initial duration* • Anaerobic coverage for aspiration
pneumonia (CAP) ¹	Q24h	7 days for complicated pneumonia is not routinely warranted
	PLUS	pneumonia* unless:
With NO recent	Azithromycin 500 mg	• Lung abscesses
hospitalization (3 months)	IV/PO X5 days OR	Complicated \bigvee \circ Empyema
AND no prior respiratory isolation of <i>Pseudomonas</i>	doxycycline 100mg	pneumonia: structural • β -lactam substitution for patients with
aeruginosa or MRSA (within 1	IV/PO Q12h (if macrolide	lung disease, severe delayed immunologic reactions or mod/severe COPD, organ-specific reactions β-lactam allergy
year)	intolerance/allergy)	8···· • • • • • • • • • • • • • • • • •
ycar)	intolerance/anergy)	confirmed(e.g. DRESS, SJS, AIN) OR a severestaphylococcus orcephalosporin allergy where structurally
		pseudomonas, and/or dissimilar antibiotic is unavailable (see
		immunosupression ⁴ cross-reactivity chart): Levofloxacin 750
		mg ¹ IV/PO Q24h
		*Longer durations of • Consider doxycycline as an alternative to
	5 days of therapy for	
	Uncomplicated CAP	indicated, depending QTc prolongation
	patients	upon clinical response o QTc prolongation (>500ms)
		• Hypokalemia
		5 days if afebrile with o Hypomagnesemia
		<2 signs of clinical Significant bradycardia
		instability on days 3-5 o Uncompensated heart failure
		• Patients receiving class IA or
		Signs of Clinical class III antiarrhythmic drugs
Signs of clinical instability impacting determination for		 Instability: Arterial O2 sat ≤ Non-severe CAP**: Do not routinely obtain respiratory OP blood cultures OP
		00%
		• $HR > 100 \text{ hpm}$ Legionella urinary antigens
		• $BR > 24$ • Severe CAP**: Obtain respiratory culture
	therapy duration	breaths/min AND blood cultures AND Legionella
		• $BP \le 90 \text{ mmHg}$ • $Patients should be switched from IV to PO$
		• Altered mental when they are hemodynamically stable,
		status (vs. baseline)

Prior to confirmation of pathogen

§ 1. Refer to antibiotic dosing tables for dose adjustments in renal dysfunction.

Reviewed/ Approved by: Antimicrobial Subcommittee: 2011; 10/2016, 9/2018; 1/2019; 9/2018, 4/2019; 7/2020, 6/2023; P & T Committee 2011, 12/2016, 7/23; Last updated 11/2023 Contributors: Curtis Collins, PharmD, Anu Malani, MD



improving clinically, and able to tolerate PO medications.

• Total duration (IV plus PO step down) described in previous column

•

- Options for PO step down therapy should target isolated pathogen. Options for PO step-down if no sputum cultures drawn or if no pathogen identified on respiratory/blood culture(s):
 - Amoxicillin/clavulanate 875mg Q12h¹ PLUS/MINUS azithromycin
 - Amoxicillin 1g Q8h¹ PLUS/MINUS azithromycin
 - Cefdinir 300mg Q12h¹ PLUS/MINUS azithromycin
 - Cefuroxime 500mg Q12h¹ PLUS/MINUS azithromycin
 - PO stepdown for patients with severe delayed immunologic reactions or organ-specific reactions β-lactam allergy (e.g. DRESS, SJS, AIN) OR penicillin or cephalosporin allergy where structurally dissimilar antibiotic is unavailable: Levofloxacin 750mg Q24h¹

[§] Prior to confirmation of pathogen

^{1.} Refer to antibiotic dosing tables for dose adjustments in renal dysfunction.

Reviewed/ Approved by: Antimicrobial Subcommittee: 2011; 10/2016, 9/2018; 1/2019; 9/2018, 4/2019; 7/2020, 6/2023; P & T Committee 2011, 12/2016, 7/23; Last updated 11/2023 Contributors: Curtis Collins, PharmD, Anu Malani, MD